AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
244.25
-0.43 (-0.18%)
4:00:00 PM EDT: $244.26 +0.01 (+0.00%)
Products

FDA Notifies Amgen Of Misbranding Of Its Biological Product, Neulasta

Published: 07/14/2021 19:43 GMT
AMGEN Inc. (AMGN) - FDA Notifies Amgen of Misbranding of Its Biological Product, Neulasta, Due to False Or Misleading Promotional Communications About Product's Benefit.
FDA Says Requests That Amgen Cease Any Violations of Federal Food, Drug & Cosmetic Act.
FDA Says Determined Claims, Presentations by Amgen for Neulasta Are Not Supported Due to Multiple Limitations of Study's Design, Analytic Strategy.
Further Company Coverage: Amgno ((reuters.
Briefs@thomsonreuters.
Com;)).